GlobeNewswire Inc.··SanofiSanofi's Lunsekimig Clears Key Phase 2 Goals in Asthma, Nasal Polyps
Sanofi's lunsekimig met primary endpoints in Phase 2 asthma and nasal polyps trials but failed in atopic dermatitis, advancing respiratory programs with favorable safety.
SNYatopic dermatitisimmunology